Cited by 287Cancer-related Molecular PathwaysTelomeres, Telomerase, and SenescencePI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

The meaning of p16ink4aexpression in tumors: Functional significance, clinical associations and future developments

Open access

Witkiewicz, Agnieszka K., Knudsen, Karen E., Dicker, Adam P., Knudsen, Erik S.·2011·Cell Cycle

DOI 10.4161/cc.10.15.16776PMC PMC3685613

Open this paper in CoChat — free account Open PDF

Abstract

The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16(ink4a). Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16(ink4a) in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16(ink4a) expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16(ink4a) expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16(ink4a) represents an ideal marker for considering RB-pathway function, tumor heterogeneity, and novel means for directing therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4161/cc.10.15.16776

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R. H., Weber, R. S., Rosenthal, D. I., Nguyen‐Tan, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C. S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,573
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“The p16 protein was identified as a low molecular weight protein bound to cyclin dependent kinase 4 and 6 (CDK4 and CDK6).(1,2) This biochemical characterization was largely facilitated by the finding that in tumor cells transformed by SV40 the sole form of CDK4 that was detectable was in complex with p16.”
Background
The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
Fakhry, C., Westra, W. H., Li, S., Cmelak, A. J., Ridge, J. A., Pinto, H. A., Forastiere, A. A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,777
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Initially, it was observed that the gene encoding CDKN2A was mutated or silenced in a wide spectrum of tumor types and cell lines.(20,21) Particularly, loss or epigenetic silencing of CDKN2A is very common in cell lines, suggesting that the process of cell culture selects against the expression of p16.”
Background
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986

Flagged first, then by citations

Show all 62 references

Research works printed but not linked: 7

Sherr CJ, 2000, Harvey Lect, 96, 73
Sherr CJ, 1992, Ciba Found Symp, 170, 209
de Jonge HJ, 2009, Aging (Albany, NY Online), 1, 949
Hruban RH, 2000, Clin Cancer Res, 6, 2969
Henshall SM, 2001, Clin Cancer Res, 7, 544
Otterson GA, 1994, Oncogene, 9, 3375
Lee CT, 1999, Clin Cancer Res, 5, 977

Sorted by citations

Items 201–287 of 287

Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions
Elhadj, M. B., Fourati, A., Amine, O. E., Goucha, A., May, A. E., May, M.-V. E., & Baizig, N. M. (2020) · Annals of Otology Rhinology & Laryngology · doi:10.1177/0003489420918280 · Cited by 6
A Multidimensional Systems Biology Analysis of Cellular Senescence in Ageing and DiseasePreprint
Avelar, R. A., Ortega, J. G., Tăcutu, R., Tyler, E. J., Bennett, D. F., Binetti, P., Budovsky, A., Chatsirisupachai, K., Johnson, E., Murray, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/743781 · Cited by 6
High human papillomavirus viral load and local immune dysregulation are associated with poor clinical outcomes in patients with cervical cancer
Mei, X., Fobian, S., IJff, M., Crezee, J., van Bochove, G. G. W., van Lonkhuijzen, L. R. C. W., Mom, C. H., van den Broek, C. B. M., Köster, J., de Koning, W., et al. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101924 · Cited by 5
Introducing Circulating Vasculature-Related Transcripts as Biomarkers in Coronary Artery Disease
Abdallah, H. Y., Fareed, A., Abdelmaogood, A. K. K., Allam, S. F. A., Abdelgawad, M., & Eldeen, L. A. T. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00622-1 · Cited by 5
Efficient derivation of immortalized, isogenic cell lines from genetically defined murine hepatoblastomas
Wang, H., Lu, J. L., Chen, K., Ma, B., Henchy, C., Knapp, J., Ranganathan, S., & Prochownik, E. V. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152478 · Cited by 5
Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors
Liu, S., Chang, Y., Ma, J., Xu, L., LI, X., Fan, J., Huang, R., Duan, G., & Sun, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1610 · Cited by 5
Novel p16 binding peptide development for p16-overexpressing cancer cell detection using phage display
Khemthongcharoen, N., Ruangpracha, A., Sarapukdee, P., Rattanavarin, S., Jolivot, R., Jarujareet, U., Plaimas, K., Bhattarakosol, P., Patumraj, S., & Piyawattanametha, W. (2015) · Journal of Peptide Science · doi:10.1002/psc.2726 · Cited by 5
Prevalence of human papillomavirus in oral squamous cell carcinomas in northern Spain
Rodríguez‐Santamarta, T., Rodrigo, J. P., Garcia-Pedrero, J. M., Álvarez–Teijeiro, S., Villaronga, M. Á., Suárez–Fernández, L., Álvarez‐Argüelles, M. E., Astudillo, A., & de Vicente, J. C. (2016) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-016-4152-9 · Cited by 5
Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate
Lee, D.-H., Yu, E., Aldahl, J., Yang, J., He, Y., Hooker, E., Le, V. L., Mi, J., Olson, A. W., Wu, H., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211153 · Cited by 6
Preferential killing of melanoma cells by a p16-related peptide
Soo, J. K., Castle, J. T., & Bennett, D. C. (2023) · Biology Open · doi:10.1242/bio.059965 · Cited by 4
The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma
Rezaei, A., Shayan, N., Shirazinia, S., Mollazadeh, S., & Ghiyasimoghaddam, N. (2023) · Reports of Biochemistry and Molecular Biology · doi:10.61186/rbmb.12.1.83 · Cited by 4
Expression of p16 protein in infantile hemangioma
Wang, S., & Wei, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.3418 · Cited by 3
Overcoming Endocrine Resistance in Breast Cancer
Ferrari, P., & Nicolini, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00029-6 · Cited by 3
Advanced Molecular Characterisation in Relapsed and Refractory Paediatric Acute Leukaemia, the Key for Personalised Medicine
Galán‐Gómez, V., Matamala, N., Ruz-Caracuel, B., Valle-Simón, P., Ochoa-Fernández, B. M., Guerra‐García, P., Pernas, A., Minguillón, J., González, B., Martínez-Romera, I., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060881 · Cited by 3
Expression analysis of cell cycle related lncRNAs in breast cancer tissues
Hussen, B. M., Taheri, M. N., Moghadam, K. B., Gholipour, M., Eslami, S., Nicknam, A., Hidayat, H. J., Ghafouri‐Fard, S., & Hafez, A. A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154453 · Cited by 3
Genetic alterations of Cyclin D-CDK4/6-INK4-RB pathway in prostate cancer
Sivoňová, M. K., Híveš, M., Kliment, J., Dusenka, R., Grendár, M., Evin, D., Kaplán, P., Brožová, M. K., VILČKOVÁ, M., Vondrák, A., et al. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10531-1 · Cited by 3
Ectopic High Expression of E2-EPF Ubiquitin Carrier Protein Indicates a More Unfavorable Prognosis in Brain Glioma
Zhang, X., Zhao, F., Zhang, S., & Song, Y. (2017) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2016.0281 · Cited by 3
Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review
Wu, J., Wang, W., Shao, X., Lin, G., & Wang, X. (2022) · Medicine · doi:10.1097/md.0000000000032238 · Cited by 2
Exploring solute carriers as biomarkers and therapeutic targets in esophageal squamous cell carcinoma
Zhang, L., Wu, X., Zhang, H., Li, E., Xu, L., & Long, L. (2025) · International Journal of Cancer · doi:10.1002/ijc.70080 · Cited by 2
Reviving p18INK4c: Harnessing a tumor suppressor for cancer treatment
Jerka, D., Bonowicz, K., Bai, Y., Reiter, R. J., Żuryń, A., & Gagat, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152674 · Cited by 2
Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response
Knudsen, E. S., O’Connor, T. N., & Witkiewicz, A. K. (2025) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2502030015 · Cited by 2
Self-citation
Exosomes from Adipose Tissue Mesenchymal Stem Cells, a Preliminary Study for In Vitro and In Vivo Application
Huynh, T. D., Isacco, C. G., Ngo, Q. N., Nguyen, B. T., Nguyen, T. H. N., Bui, T. M. D., Minh, V. N., Truong, K. D., Chau, T. V., Truong, H. C., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12101129 · Cited by 2
Clinicopathological features and mutational landscape of colorectal cancer subgroups defined by MSI and EMAST status
Čaćev, T., Đerfi, K. V., Salar, A., Marinović, S., Zapletal, E., Musani, V., Škrtić, A., Pačić, A., & Kapitanović, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156302 · Cited by 2
Hepatoblastoma Cell Lines: Past, Present and Future
Prochownik, E. V., Henchy, C., & Wang, H. (2025) · Cells · doi:10.3390/cells14242013 · Cited by 2
Bowen's disease with features resembling myrmecia wart
Hsu, C., Chen, Y., Yang, W., Hsu, K., Chao, S., & Lee, J. Y. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12691 · Cited by 2
Expression and therapeutic targeting of BMI1 in canine gliomas
Al‐Nadaf, S., Peacott‐Ricardos, K. S., Dickinson, P. J., Rebhun, R. B., & York, D. S. (2022) · Veterinary and Comparative Oncology · doi:10.1111/vco.12852 · Cited by 2
Multimodal assessment of high-risk human papillomavirus in sinonasal squamous cell carcinoma
Zhou, A., Sharma, A., Kuhnell, D., Hinrichs, B. H., Kendler, A., Wang, J., McKillip, K. D., Tang, A. L., Takiar, V., Wise-Draper, T. M., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155486 · Cited by 2
Expression of p16 Tumor Suppressor Protein in Malignant Ovarian Germ Cell Tumors; Immunohistochemical Study
Hosny, G., Ahmed, O. A., Ahmed, R. M., & Fadel, S. A. M. (2023) · International Journal of Surgical Pathology · doi:10.1177/10668969231168358 · Cited by 2
Useful immunohistochemical indicators in canine mast cell tumours
Kandefer-Gola, M., Nowak, M., MADEJ, J. A., Dzimira, S., CIAPUTA, R., & Janus, I. (2015) · Acta Veterinaria Hungarica · doi:10.1556/avet.2015.005 · Cited by 2
Precision Medicine Based on Next-Generation Sequencing and Master Controllers
Dukleska, K., Yeo, C. J., Pishvaian, M. J., & Brody, J. R. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_71 · Cited by 2
The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer
de Brot, S., & Mongan, N. P. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_22 · Cited by 2
A Molecular Implicatory Propositioning Roles for Human Cytomegalovirus and P16 Gene Expression in Oral Squamous Cellular Carcinogenesis
Sachit, H. G., Almahbobi, T. F., Ali, Z. M. M., Ali, S. H. M., & Al-Alwany, S. H. M. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.4.49 · Cited by 2
Molecular subtypes of urothelial carcinomas of the bladder in young patients
Meshcheryakov, I. A., Андреевич, К. К., Митин, Н. П., Ponomareva, E. V., & Shelekhova, K. V. (2021) · JOURNAL of SIBERIAN MEDICAL SCIENCES · doi:10.31549/2542-1174-2021-3-82-104 · Cited by 2
Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
Maylina, L., Kambayashi, S., Baba, K., Igase, M., Mizuno, T., & Okuda, M. (2022) · Journal of Veterinary Medical Science · doi:10.1292/jvms.22-0498 · Cited by 2
p16 Immunohistochemical Patterns in Triple-Negative Breast Cancer: Clinical and Genomic Similarities of the p16 Diffuse Pattern to pRB Deficiency
Lee, M., Lee, A., Choi, B., Park, W. C., Lee, J., & Kang, J. K. (2024) · Pathobiology · doi:10.1159/000541299 · Cited by 1
Association between p16INK4A expression and a treatment response to CDK4/6 inhibitor in advanced breast carcinoma
Huang, X. Y., Harada, S., Shi, W., Siegal, G. P., Anderson, S. A., Şahin, A. A., Khoury, K. E., & Yalnız, C. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105905 · Cited by 1
Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Cornish, N., Ward, R., Warkentin, M. T., Thirlwell, C., Mumford, A. D., Westbury, S. K., & Haycock, P. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.019 · Cited by 1
Site-specific phosphorylation modulates p16/CDK4 binding dynamics and energetics: Insights from molecular simulations
Tella, P. V., & Rath, S. L. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153754 · Cited by 1
Multidisciplinary management of meningiomas in the era of precision oncology
Assadi, M., Juweid, M. E., Lohmann, P., Minniti, G., Sahm, F., Ivanidze, J., Karschnia, P., Landry, A., Mottaghy, F. M., & Zadeh, G. M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01148-9 · Cited by 1
CDK inhibitors in hormone receptor positive advanced breast cancer
Aktaş, B. (2015) · Marmara medical journal · doi:10.5472/mmj.77406 · Cited by 1
Stable H-bond networks are crucial for selective CDK4 inhibition revealed from comprehensive in silico investigation
Zhang, Z., Hu, B., Joseph, J., Wang, Y., Mao, J., Zhang, H., Ma, Q., Zhang, Y., & Wang, J. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107699 · Cited by 1
Non-canonical approaches to targeting hypoxic tumors.
Zhao, S., & El‐Deiry, W. S. (2022) · PubMed · Cited by 1
Evaluation of Cellular Changes and Immunohistochemistry Expression of p53 and p16 in the Oral Mucosa Among Saudi Smokers
Elmahdi, F. M. A., Mostafa, H. E., Eldib, A. M. A., Youssef, M., Alahmadi, L. S., Alkurdi, A. A., & Hussein, H. M. (2024) · Cureus · doi:10.7759/cureus.55027 · Cited by 1
Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant
Patel, R. J., Fountzilas, C. K., Horowitz, M., Schultz, E., Clayback, K. M., Knudsen, E. S., Witkiewicz, A. K., & Onel, K. (2025) · Familial Cancer · doi:10.1007/s10689-025-00475-7 · Cited by 1
Self-citation
Molecular and genetic profile of head and neck squamous cell carcinoma
Stukan, А. I., Porhanov, V. A., Bodnya, V. N., Chuhraj, O. Y., Makarova, Y. M., & Семенович, Э. И. (2018) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2018-9-3-50-57 · Cited by 1
Mapping of human papilloma virus, p16, and epstein‐barr virus in non‐malignant tonsillar disease
Holm, A., Schindele, A., Allard, A., Eriksson, I., Sandström, K., Laurell, G. F. E., Nylander, K., & Olofsson, K. (2019) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.260 · Cited by 1
Integrating Context of Tumor Biology and Vaccine Design to Shape Multidimensional Immunotherapies
Wang, N. S., & Maine, C. J. (2020) · Future Drug Discovery · doi:10.4155/fdd-2019-0031 · Cited by 1
Examining Autophagy and Mitophagy as Inducible Mechanisms of Cellular Remodelling
Bloemberg, D. (2017) · UWSpace (University of Waterloo) · Cited by 1
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid TumorsPreprint
Seetharam, M., Norman, A., Allred, J. B., Kong, J., Opyrchal, M., Ma, W. W., Lou, Y., Dy, G. K., Mahipal, A., Weroha, S. J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4261257/v1 · Cited by 1
Tumor suppressor expression and genetic characterization of benign and malignant chondroid syringoma
Williams, D. L., Olsen, R. J., Coffey, D. M., Hendrickson, H. L., Hamilton, C., & Cagle, P. T. (2014) · Case Reports in Clinical Pathology · doi:10.5430/crcp.v2n1p28
Molecular Therapeutics: Pancreatic Cancer
Fogelman, D. R., Javle, M. M., & Abbruzzese, J. L. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch26
ORIGINAL ARTICLE p16 INK4A Represses the paracrine tumor-promoting effects of breast stromal fibroblasts
Al‐Ansari, M. M., & Shehata, A. I. (2012)
[Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion].
He, B. L., Xu, N., Li, Y. L., Pan, C. Y., Cao, R., Liao, L. B., Yin, C., Lan, Y. Q., Lu, Z., Huang, J., et al. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.03.006
Ageing Astrocytes - Implications for Motoneuron Dysfunction and Sarcopenia
Arpel, C. (2017) · Otago University Research Archive (University of Otago)
The Emerging Roles of Circular RNAs in Colorectal Cancer
Ge, J., & Zhang, X. (2019) · Research in Health Science · doi:10.22158/rhs.v4n2p126
Application of p16, p63, cyclin D1 immunostaining and nuclear morphometric analysis for assessment of cervical dysplasia
Vukomanović-Djurdjević, B., Andrejić-Višnjić, B., Perić, A., Nenadić, D. B., & Baletić, N. (2020) · Vojnosanitetski pregled · doi:10.2298/vsp200818087v
Expression of Ki-67, Cyclin D1, P53, and P16 in patients with oral leukoplakia and leukoplakia cancerization with spicy diet in Chengdu.
Wan, Z.-X., Zheng, Z., Huang, M.-C., Chen, Y., & Yao, L.-H. (2021) · PubMed Central · doi:10.7518/hxkq.2021.04.009
Cancer and cell cycle
Nair, R. R., & Yadav, S. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99883-3.00013-5 · Cited by 1
Precision Medicine Based on Next Generation Sequencing and Master Controllers
Dukleska, K., Yeo, C. J., Pishvaian, M. J., & Brody, J. R. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_71-1
Molecular Characteristics
Lin, G. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2374-8_6
Increased cytotoxicity of Irinotecan or 5FU by expression of p16 INK4a in A549 lung carcinoma cellPreprint
Eizadkhah, A., Afsari, N. S., Ostad, S. N., Nourian, Y. H., & Ghahremani, M. H. (2022) · Research Square · doi:10.21203/rs.3.rs-2290176/v1
CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Mir, M. A., & Jan, U. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_14
Neoplasms of the Pharynx
Wenig, B. M., & Hernandez-Prera, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-71257-6.00010-1
The Intersection of Genetic and Molecular Biology in Oral Potentially Malignant Disorders: Identifying Key Biomarkers and Pathways for Clinical Intervention
Hema Shree, K. (2024) · International Journal of Histopathological Interpretation · doi:10.56501/intjhistopatholinterpret.v13i2.1133
Global Burden, Risk factors and Pathobiology of Malignant Neoplasms of the Oral Mucosa and the Oropharynx
Hankinson, P., & Khurram, S. A. (2024) · Wiley eBooks · doi:10.1002/9781119989233.ch28
Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
Norman, A., Seetharam, M., Allred, J. B., Kong, J., Opyrchal, M., Ma, W. W., Lou, Y., Dy, G. K., Mahipal, A., Weroha, S. J., et al. (2025) · BJC Reports · doi:10.1038/s44276-024-00107-0 · Cited by 1
An immunohistochemical characterization of basal cell carcinoma in patients below 40 years of age
Waller, V., Boeschen, M., Lingscheidt, T., Stiller, M., Eickenscheidt, L., Wilhelm, T., Grunewald, S., Ziemer, M., Simon, J. C., Bläker, H., et al. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15819
Comparative Evaluation of Three Primary Antibody Clones for p16 Immunohistochemistry in Gynecologic Tumors
Yoshida, H., Sugitani, A., Kato, M. K., Uno, M., & Ishikawa, M. (2025) · Antibodies · doi:10.3390/antib14030077
Associations of tumour somatic mutations with cancer-associated venous thromboembolismPreprint
Cornish, N., Ward, R., Warkentin, M. T., Thirlwell, C., Mumford, A. D., Westbury, S. K., & Haycock, P. (2025) · medRxiv · doi:10.1101/2025.09.16.25335936
Eine immunhistologische Charakterisierung des Basalzellkarzinoms bei Patienten unter 40 Jahren
Waller, V., Boeschen, M., Lingscheidt, T., Stiller, M., Eickenscheidt, L., Wilhelm, T., Grunewald, S., Ziemer, M., Simon, J., Bläker, H., et al. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15819_g
Passive nuclear transport deviates from Fickian behavior in prostate and breast cell types
Scott, N. R., Lin, A., Belardi, B., & Parekh, S. H. (2026) · Nucleus · doi:10.1080/19491034.2026.2620223
The likely possibility of predicting treatment outcomes of cervical lesions using serum FOXP3 and P16INK4A as shown by a cohort study in South Western Uganda
Ssedyabane, F., Tusubira, D., Niyonzima, N., Najjuma, J. N., Randall, T. C., Kajabwangu, R., Castro, C. M., Lee, H., & Ngonzi, J. N. J. (2026) · Discover Oncology · doi:10.1007/s12672-026-04670-5
Involvement of microglial aging in neurodegenerative diseases: a focus on amyotrophic lateral sclerosis
Catalano, M., & Limatola, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00004-8
Reprogrammation comportementale : modèles, algorithmes et application aux maladies complexes
Biane, C. (2018) · theses.fr (ABES) · doi:10.70675/2c367370z3ea6z46cez997czc25478fd2287
Generation of antisense RNAs at convergent gene loci in cells undergoing senescence
Deb, M. K. (2016) · theses.fr (ABES) · doi:10.70675/739ebf07zf620z4e1fzb0d4z02066589491f
Caractérisation de la sénescence des cardiomyocytes et identification de marqueurs associés
Maggiorani, D. (2017) · theses.fr (ABES) · doi:10.70675/a58747bczd60bz4482za3b2z7ae33d26ffa4
Medecine personalisée et recherche des biomarqueurs à une thérapie ciblée dans le cancer du sein : L'exemple des inhibiteurs CDK4/6
Ballester, M. A. (2019) · theses.fr (ABES) · doi:10.70675/9b18708ez95f5z42adz9479z32a97604ddcf
Towards selective bifunctional senolytic compounds : design, mechanistic studies and proof of concept
Dotou, M. (2023) · theses.fr (ABES) · doi:10.70675/ea22a042z96ccz45fdz9667z82a8825cb567
Mechanisms of cell cycle regulation by CDK4 / 6 and pathways for the formation of resistance to their inhibitors (literature review)
Kutsebko, D. N., & Glushakov, R. I. (2026) · Malignant tumours · doi:10.18027/2224-5057-2026-067
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development
Kamakura, N., Jo, M., Takahashi, M., & Hirota, T. (2026) · Cancer Science · doi:10.1111/cas.70438
Human papillomavirus (HPV) and p16INK4a expression in early-onset prostate cancer
AVCI, İ. E., Yılmaz, H., Sayan, M., Baynal, E. A., & Bayrak, B. Y. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05218-w
Integrated computational evaluation of potential CDK4 inhibitors for breast cancer therapy
Pham, E. C., Van, L. V., Le, K. A. T., Do, T. T. H., & Truong, T. N. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103597
Cyclin-dependent kinases as signaling integrators in cancer: Structural evolution, functional plasticity, and drug discovery
Upadhyay, S., Khan, S., Bhardwaj, M., & Hassan, M. I. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168364
The impact of physiological oxidants on triggering amyloid formation of the cell cycle regulator protein p16 INK4A
Smith, B. R., Magon, N. J., Sethi, A., Gray, S. G., Heath, S. G., Morris, V. K., & Göbl, C. (2026) · Protein Science · doi:10.1002/pro.70723 · Cited by 1
CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025)
Wang, C., Zhang, Y., Bao, S., Huang, X., Wang, C., & Zhang, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110565
BindingDB Entry 50017151: Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
BindingDB (2023) · UC San Diego · doi:10.7270/q2bv7mpd

Authors: Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S.
Affiliations: Thomas Jefferson University (US)
Corresponding author: Knudsen, Erik S.
ORCID: Witkiewicz, Agnieszka K.
Knudsen, Karen E.
Dicker, Adam P.
Knudsen, Erik S.
Venue: Cell Cycle
Publisher: Informa UK Limited
Published: 2011-08
Volume: 10
Issue: 15
Pages: 2497-2503
ISSN: 1538-4101 (ISSN-L)
1551-4005
DOI: 10.4161/cc.10.15.16776
PMC: PMC3685613
OpenAlex: W2019517928
Cited by: 286
References: 62
Citations by year: 2026: 14 · 2025: 22 · 2024: 14 · 2023: 22 · 2022: 29 · 2021: 16 · 2020: 26 · 2019: 26 · 2018: 24 · 2017: 18 · 2016: 13 · 2015: 19 · 2014: 14 · 2013: 19 · 2012: 10
FWCI: 1.26
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cell Cycle (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA099996)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p16INK4a, CDKN2A, tumor suppressor, Rb pathway, cellular senescence, tumor heterogeneity, prognosis, treatment response, tumor progression, CDK4/6 inhibition
MeSH terms: Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Retinoblastoma Protein, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cyclin D

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The meaning of p16ink4aexpression in tumors: Functional significance, clinical associations and future developments

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks